Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells

Molecular Endocrinology

Volumn 28, Issue 6, 2014, Pages 872-885

  Jaganathan, Anbalagan ^a   Chaurasia, Pratima ^b   Xiao, Guang Qian ^c   Philizaire, Marc ^d   Lv, Xiang ^e   Yao, Shen ^b,d   Burnstein, Kerry L ^f,g   Liu, De Pei ^e   Levine, Alice C ^b   Mujtaba, Shiraz ^a,d  

^a Department of Structural and Chemical Biology ^*  (United States)

^b Tisch Cancer Institute   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e CITY UNIVERSITY OF NEW YORK   (United States)

^f INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; HISTONE H4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MYST1; REGULATOR PROTEIN; SIRTUIN 1; TRANSCRIPTION FACTOR E2F1; TUMOR PROTEIN; TUMOR PROTEIN D52; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; CELL CYCLE PROTEIN; HISTONE ACETYLTRANSFERASE; KAT8 PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; DEACETYLATION; DOWN REGULATION; G2 PHASE CELL CYCLE CHECKPOINT; LNCAP CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; ACETYLATION; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN PROCESSING; TUMOR CELL LINE;

ACETYLATION; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; SIRTUIN 1; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901928280     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1055     Document Type: Article

References (58)

1. Shiota M, Yokomizo A, Masubuchi D, et al. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate. 2010;70:540-554.
2. Cronauer MV, Culig Z. Molecular aspects of prostate cancer. World J Urol. 2012;30:277-278.
3. Culig Z, Santer FR. Androgen receptor co-activators in the regulation of cellular events in prostate cancer. World J Urol. 2012;30: 297-302.
4. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem. 2002; 277:25904-25913.
5. Halkidou K, Gnanapragasam VJ, Mehta PB, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003;22:2466-2477.
6. Brady ME, Ozanne DM, Gaughan L, et al. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem. 1999;274:17599-17604.
7. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
8. Basu S, Tindall DJ. Androgen action in prostate cancer. Horm Cancer. 2010;1:223-228.
9. Huang H, Tindall DJ. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr. 2002;12:193-207.
10. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39.
11. Nadiminty N, Lou W, Sun M, et al. Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells. Cancer Res. 2010;70:3309-3319.
12. Nelius T, Filleur S, Yemelyanov A, et al. Androgen receptor targets NFκB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer. 2007;121:999-1008.
13. Nadiminty N, Dutt S, Tepper C, Gao AC. Microarray analysis reveals potential target genes of NF-κB2/p52 in LNCaP prostate cancer cells. Prostate. 2010;70:276-287.
14. Kadowaki Y, Chari NS, Teo AE, Hashi A, Spurgers KB, McDonnell TJ. PI3 kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells. Apoptosis. 2011;16:627-635.
15. Altintas DM, Shukla MS, Goutte-Gattat D, et al. Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol Endocrinol. 2012;26:1531-1541.
16. Chen H, Tini M, Evans RM. HATs on and beyond chromatin. Curr Opin Cell Biol. 2001;13:218-224.
17. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15-23.
18. Fu M, Wang C, Zhang X, Pestell RG. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol. 2004; 68:1199-1208.
19. Fu M, Liu M, Sauve AA, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol. 2006;26:8122-8135.
20. Fu M, Rao M, Wang C, et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003;23:8563-8575.
21. Fu M, Rao M, Wu K, et al. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem. 2004;279:29436-29449.
22. Fu M, Wang C, Reutens AT, et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000;275:20853-20860.
23. Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 2004;64:3814-3822.
24. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310.
25. Natoli G, Ghisletti S, Barozzi I. The genomic landscapes of inflammation. Genes Dev. 2011;25:101-106.
26. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446: 475-482.
27. Chen PC, Lin TH, Cheng HC, Tang CH. CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells. Carcinogenesis. 2012;33:937-945.
28. Zhang L, Altuwaijri S, Deng F, et al. NF-κB regulates androgen receptor expression and prostate cancer growth. Am J Pathol. 2009;175:489-499.
29. Mellert HS, McMahon SB. hMOF, a KAT(8) with many lives. Mol Cell. 2009;36:174-175.
30. Yuan H, Rossetto D, Mellert H, et al. MYST protein acetyltransferase activity requires active site lysine autoacetylation. EMBO J. 2012;31:58-70.
31. Sykes SM, Mellert HS, Holbert MA, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell. 2006;24:841-851.
32. Lu L, Li L, Lv X, Wu XS, Liu DP, Liang CC. Modulations of hMOF autoacetylation by SIRT1 regulate hMOF recruitment and activities on the chromatin. Cell Res. 2011;21:1182-1195.
33. Sharma GG, So S, Gupta A, et al. MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and doublestrand break repair. Mol Cell Biol. 2010;30:3582-3595.
34. Carrozza MJ, Utley RT, Workman JL, Côté J. The diverse functions of histone acetyltransferase complexes. Trends Genet. 2003;19: 321-329.
35. Gupta A, Guerin-Peyrou TG, Sharma GG, et al. The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol. 2008; 28:397-409.
36. Smith ER, Cayrou C, Huang R, Lane WS, Côté J, Lucchesi JC. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol. 2005;25:9175-9188.
37. Mendjan S, Taipale M, Kind J, et al. Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell. 2006;21:811-823.
38. Pfister S, Rea S, Taipale M, et al. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer. 2008;122:1207-1213.
39. Song JS, Chun SM, Lee JY, Kim DK, Kim YH, Jang SJ. The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Korean J Pathol. 2011;45:386-396.
40. Wang Y, Zhang R, Wu D, et al. Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J Exp Clin Cancer Res. 2013;32:8.
41. Dai JL, Maiorino CA, Gkonos PJ, Burnstein KL. Androgenic upregulation of androgen receptor cDNA expression in androgenindependent prostate cancer cells. Steroids. 1996;61:531-539.
42. Mujtaba S, He Y, Zeng L, et al. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell. 2002;9: 575-586.
43. Mujtaba S, He Y, Zeng L, et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell. 2004;13:251-263.
44. Mujtaba S, Manzur KL, Gurnon JR, Kang M, Van Etten JL, Zhou MM. Epigenetic transcriptional repression of cellular genes by a viral SET protein. Nat Cell Biol. 2008;10:1114-1122.
45. Hechtman JF, Xiao GQ, Unger PD, Kinoshita Y, Godbold JH, Burstein DE. Anti-glutamate receptor 2 as a new potential diagnostic probe for prostatic adenocarcinoma: a pilot immunohistochemical study. Appl Immunohistochem Mol Morphol. 2012;20:344-349.
46. Mujtaba S, Winer BY, Jaganathan A, et al. Anthrax SET protein: a potential virulence determinant that epigenetically represses NF-κB activation in infected macrophages. J Biol Chem. 2013;288: 23458-23472.
47. Allis CD, Berger SL, Cote J, et al. New nomenclature for chromatinmodifying enzymes. Cell. 2007;131:633-636.
48. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κBas the matchmaker. Nat Immunol. 2011;12:715-723.
49. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 1996;384:641-643.
50. Patel J, Pathak RR, Mujtaba S. The biology of lysine acetylation integrates transcriptional programming and metabolism. Nutr Metab (Lond). 2011;8:12.
51. Ummanni R, Teller S, Junker H, et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 2008;275:5703-5713.
52. Huang WC, Chan ST, Yang TL, Tzeng CC, Chen CC. Inhibition of ICAM-1 gene expression, monocyte adhesion and cancer cell invasion by targeting IKK complex: molecular and functional study of novel α-methylene-γ-butyrolactone derivatives. Carcinogenesis. 2004;25:1925-1934.
53. Chen YC, Lu PH, Hsu JL, Yu CC, Guh JH. ICAM-1 and AMPK regulate cell detachment and apoptosis by N-methyl-N+-nitro-Nnitrosoguanidine, a widely spread environmental chemical, in human hormone-refractory prostate cancers. Toxicol Appl Pharmacol. 2011;257:412-419.
54. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8:440-448.
55. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer. 2002;9:155-170.
56. Li X, Wu L, Corsa CA, Kunkel S, Dou Y. Two mammalian MOF complexes regulate transcription activation by distinct mechanisms. Mol Cell. 2009;36:290-301.
57. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-κB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis. 2000;18:471-479.
58. Sun HZ, Yang TW, Zang WJ, Wu SF. Dehydroepiandrosteroneinduced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway. J Endocrinol. 2010;204: 311-318.